ExonHit Bets on Sapio LIMS



By John Russell

Sept. 11, 2008 | The laboratory information management system (LIMS) market has long had a reputation for being a messy place where giant and tiny vendors compete with internally developed software. Among the criticisms commonly lobbed at commercial vendors are: that their products inevitably require major customization; that customization is difficult and costly; and that once installed their products are inflexible and difficult to change. Yet these lingering ideas may no longer reflect reality.

It’s still not a huge market. Health Industry Insights estimates LIMS sales in the U.S. at $184.5M for 2007 and at $348.3M worldwide. “LIMS is a mature market and continues to move towards standardized commercial solutions and away from internally developed implementations,” says HII research director Alan Louie.

What Heather Jordan found in her search for a LIMS for biotech ExonHit was a more nuanced marketplace that fulfilled and defied its stereotype. In the end, the director of operations for ExonHit Therapeutics (who also is responsible for its Paris-based lab) was able to find a solid commercial offering – Exemplar from Sapio Sciences - whose key strengths were flexibility, ease of use, and fast deployment. Jordan’s experience is instructive and perhaps more representative of today LIMS offerings.

“We evaluated 8 to 10 different vendors. The majority of them were very well-known types of providers which you hear about all the time, such as the ABI systems and LabVantage, etc. But there were also some small software companies,” says Jordan. The chief challenge was to find a LIMS suitable for ExonHit’s growing microarray processing work and which would be compliant with 21 CFR Part 11 and other regulatory requirements. Until last January, the company had a paper-based manual system. 

ExonHit is a small Paris-based biotech founded in 1997. Its proprietary technology - DATAS (Differential Analysis of Transcripts of Alternative Splicing) – monitors alternative RNA splicing events. ExonHit applied its expertise in alternative splicing to a microarray platform and developed a novel design of probes to monitor the differences of highly similar transcripts. The company received patents on this probe configuration and currently runs a service operation that provides researchers with analyzed expression data on individual transcripts. Besides conducting internal and collaborative research programs around cancer and neurodegenerative disorders, the company also worked with Agilent Technologies to develop a commercially available version of its microarray format (SpliceArray) in late 2004.

“Agilent provided the chips to people who actually have core labs that run Agilent microarrays. At the same time, we launched a full service in-house, providing processed data and analysis to researchers,” says Jordan, based in the company’s Gaithersburg, MD, facility. “We also expanded our service offering to include the Affymetrix platform in the U.S. in 2006 and added a service lab in our Paris facility in late 2007. We can run standard gene expression microarray experiments, as well as alternative splice event profiling on our SpliceArray platform for customers on both the Agilent and Affymetrix platforms.”

Regulatory compliance led the list of Jordan’s LIMS criteria, as the company is very focused on achieving Good Laboratory Practice (GLP) status. She also wanted a single LIMS accessible to folks on either side of the Atlantic.

“We didn't want to worry about installing two different software packages. We just wanted one server that we could both access and not have issues with that. We wanted sample tracking, bar coding, reagent inventory, all of the items that go along with the electronic lab notebook, all the protocol tracking, from sample inventory, and quality assessment to QC [quality control] data,” Jordan.

The Sapio LIMS eventually chosen is hosted on a Dell PowerEdge 1950 running Windows Server 2003 R2. Because the LIMS application is written in Java, it is platform independent. The server is using an Apache web server to provide web start functionality to the LIMS user interface application. The LIMS application connects to a database server that is hosted on a Dell PowerEdge 1950 again running Windows Server 2003 R2. The DBMS installation is MySQL.

LIMS supplier responses to ExonHit’s inquiries were varied. A few big names showed little interest or were frankly and perhaps rightly discouraging. “One guy actually said to us, ‘You probably can't afford this system,’ and he didn't know what our budget was. He didn't even ask what our budget was,” Jordan says.

ExonHit is small. The U.S. staff is of roughly 20 and there are 50 in Paris. “We have four scientists here that regularly access and enter data into the LIMS, and there's an additional five or six people, such as our financial people and other managers, who access the LIMS to look at information and get reports;  the numbers are the same in our Paris facility,” says Jordan.

Three of the LIMS ExonHit evaluated were more suited for R&D. “They weren't geared toward sample tracking, data management capabilities – the processes I knew I really needed. I needed something with extensive capabilities,” she says. “For example, we have a large array inventory that includes custom arrays on the Affy[metrix] format and Agilent format, different slide array formats, as well as standard commercial arrays from these vendors – and I need to have a lot of detail on my array inventory tracking.”

Other LIMS products didn’t have needed flexibility or would have required substantial programming to make ongoing changes.

“The majority of our clients at this point are academic labs. Many want to do custom-type projects with their favorite gene lists, so Agilent is a nice flexible format for that. We have a portal on our website where researchers can go and select their favorite gene and get a splicing microarray designed for them. These customers have smaller projects, 2, 4, 8, 20 arrays. [But] we also have some pharma with large projects, hundreds of arrays.”

The result is the need to track projects that can have either hundreds of samples or projects that have two to four samples, “so we needed something that was very flexible. We needed something that was capable of not only tracking the samples that came in, but also from the time that we receive either cells or tissue or blood or the total RNA, whatever they decide to send us, we needed to be able to ensure that we could track those from receipt all the way through an array hybridization experiment.”

Jordan adds, “If we had an outlier in an experiment, it's much easier to go into the LIMS and look at lot numbers of reagents that were used or lot numbers of arrays and the date processed, the scanner information from that particular date, and actually troubleshoot and identify the problem, such as an RNA sample that failed the QC and so we eliminated that RNA sample from the study.”

Compatibility with ExonHit’s workflow and speedy deployment were also important, says Jordan. “Exemplar had a lot of array protocols and procedures already programmed in for both Affy and Agilent. It allowed for import of the data files. It just had a lot of the proper protocols already and we were really happy we could hit the ground running,” says Jordan.

Jordan was not looking for a LIMS-cum-analysis-tool-suite. ExonHit hit currently uses the Partek Genomics Suite, which is outside the LIMS. She has added some device management functions: “We can [now] take some of our data output files directly from the lab and have them parsed into the sample sheet. So data information like absorbance values and QC metrics, customized plug-ins – you push a button and it pulls all the data in and fills in all the fields and you have your yes-it-passed-QC answer and you're ready to go.”

She also purchased tablet notebooks and says they’ve been very useful. “Obviously we have a lot of computers in the lab that are hooked up to our scanners and things like that, but much of the wet chemistry can't be tracked on a computer unless they have the tablet there and can enter data as they're working; it's a time-saving thing and it's real-time accessible, so as they're working on something in the lab, I can access it at my desk in my office or the Paris office can look at the LIMS and actually see real-time what's going on and what is happening there.”

Performing due diligence on LIMS products took place last summer. Jordan presented the proposal in the fall to management, which took a couple of months to review it, and signed off towards the end of the year. In the end Jordan found two offerings that were suitable, but preferred Exemplar for its functionality and proximity (Sapio Sciences is roughly an hour away). Deployment took a few weeks, says Jordan, and was surprisingly painless for such a big piece of software. The main challenge turned out to be something she hadn’t anticipated: rethinking workflows to take advantage of the LIMS.

“I haven't done a lot of ROI [return-on-investment] measurement yet because we're working on some higher-profile projects and diagnostic collaborations that have been taking my time. We also do a lot of profiling for internal research projects, and those projects aren't considered in that number. I would say we're saving maybe 40 percent of time involved in non-experimental processes.

“A lot of my time used to be spent writing reports and taking the output files and sorting them for people, burning them on DVDs, all that kind of stuff. Now I can set up a custom report and just click a button and it consolidates all the data and generates a report for me,” she says.

Score one for the commercial vendors.

----------------------------------

This article first appeared in Bio-IT World’s Predictive Biomedicine newsletter. Click here for a free subscription.

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 





For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .